SynthesisDrugs2010
Seizure outcomes following the use of generic versus brand-name antiepileptic drugs: a systematic review and meta-analysis.
Synthesis in Drugs, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02429596 (A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs), which is not on this map. Cited by 63 papers, 5 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Randomized Controlled Trial of Generic Substitution of Antiepileptic Drugs
Who cites it
63 citing papers in PubMed, 5 syntheses or guidelines pooled it, 189 citations in OpenAlex.
- Effects of generic exchange of solid oral dosage forms in neurological disorders: a systematic review.International journal of clinical pharmacy · 2020Pooled it
- Generic versus brand-name drugs used in cardiovascular diseases.European journal of epidemiology · 2016Pooled it
- The Impact of Generic Substitution on Health and Economic Outcomes: A Systematic Review.Applied health economics and health policy · 2015Pooled it
- What do people really think of generic medicines? A systematic review and critical appraisal of literature on stakeholder perceptions of generic drugs.BMC medicine · 2015Pooled it
- Quality of reporting of bioequivalence trials comparing generic to brand name drugs: a methodological systematic review.PloS one · 2011Pooled it
- Generic-reference and generic-generic bioequivalence of forty-two, randomly-selected, on-market generic products of fourteen immediate-release oral drugs.BMC pharmacology & toxicology · 2017Trial
- Sodium Valproate-Induced Bicytopenia: A Case Report.Cureus · 2025Article
- Real-World Evidence on Levetiracetam-Induced Hypokalemia: An Active Comparator Cohort Study.Drugs - real world outcomes · 2024Article
- An audit of prescribing pattern of anti-epileptic drugs with its effect on therapeutic drug levels and seizure control at a tertiary care public hospital.Ghana medical journal · 2023Article
- Bioequivalence, Drugs with Narrow Therapeutic Index and The Phenomenon of Biocreep: A Critical Analysis of the System for Generic Substitution.Healthcare (Basel, Switzerland) · 2022Review
- Therapeutic Basis of Generic Substitution of Antiseizure Medications.The Journal of pharmacology and experimental therapeutics · 2022Review
- Generic switching: Do future physicians in Jordan have enough knowledge and a positive attitude?Frontiers in pharmacology · 2022Article
- Analysis of patients' request to switch from a generic drug to the original drug in external prescriptions.Journal of pharmaceutical health care and sciences · 2020Article
- Effectiveness at 24 Months of Single-Source Generic Carbamazepine, Lamotrigine, or Levetiracetam in Newly Diagnosed Focal Epilepsy.The Permanente journal · 2020Article
- Is greater generic competition also linked to lower drug prices in South Korea?Health economics review · 2020Article
- The Use of Generic Medications for Glaucoma.Journal of ophthalmology · 2020Review
- Considerations over a Case of Suspected Therapeutic Failure in Pediatric Patients after Switching Valproate Manufacturers.Innovations in pharmacy · 2020Article
- A Survey of Patients' Perceptions of Pill Appearance and Responses to Changes in Appearance for Four Chronic Disease Medications.Journal of general internal medicine · 2019Article
- Generic Drugs in the United States: Policies to Address Pricing and Competition.Clinical pharmacology and therapeutics · 2019Article
- Use of generic medicines in Latvia: awareness, opinions and experiences of the population.Journal of pharmaceutical policy and practice · 2019Article
3 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 2 institutions in 1 country.
Funding
Abstract
The automatic substitution of bioequivalent generics for brand-name antiepileptic drugs (AEDs) has been linked by anecdotal reports to loss of seizure control. To evaluate studies comparing brand-name and generic AEDs, and determine whether evidence exists of superiority of the brand-name version in maintaining seizure control. English-language human studies identified in searches of MEDLINE, EMBASE and International Pharmaceutical Abstracts (1984 to 2009). Randomized controlled trials (RCTs) and observational studies comparing seizure events or seizure-related outcomes between one brand-name AED and at least one alternative version produced by a distinct manufacturer. We identified 16 articles (9 RCTs, 1 prospective nonrandomized trial, 6 observational studies). We assessed characteristics of the studies and, for RCTs, extracted counts for patients whose seizures were characterized as 'controlled' and 'uncontrolled'. Seven RCTs were included in the meta-analysis. The aggregate odds ratio (n = 204) was 1.1 (95% CI 0.9, 1.2), indicating no difference in the odds of uncontrolled seizure for patients on generic medications compared with patients on brand-name medications. In contrast, the observational studies identified trends in drug or health services utilization that the authors attributed to changes in seizure control. Although most RCTs were short-term evaluations, the available evidence does not suggest an association between loss of seizure control and generic substitution of at least three types of AEDs. The observational study data may be explained by factors such as undue concern from patients or physicians about the effectiveness of generic AEDs after a recent switch. In the absence of better data, physicians may want to consider more intensive monitoring of high-risk patients taking AEDs when any switch occurs.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.